SRRK vs WST
Scholar Rock Holding Corporation vs West Pharmaceutical Services — AI-powered side-by-side comparison
SRRK
Scholar Rock Holding Corporation
57
Watch
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | SRRK | WST |
|---|
| AI Score |
57
|
74
|
| Price |
$52.11
|
$351.74
|
| P/E Ratio |
-15.73×
|
44.65×
|
| ROE |
-154.0%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
36.8%
|
| Debt / Equity |
0.80×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
60.3
|
58.0
|
| Beta |
0.666
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for SRRK versus WST.
WST leads by 17 points.
WST scores 74/100 (Buy) versus SRRK at 57/100 (Watch).
SRRK Committee View
60% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 18.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 18.3x prices in significant intangible value — Value
- ROE of only -159.1% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 18.2% signals elevated volatility — Risk
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical